Chantix Banned For Pilots; Watchdog Report Cites More Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s anti-smoking drug topped adverse-events reports in the fourth quarter of last year, nonprofit says.
You may also be interested in...
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.
Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies
Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.